thiazolidines has been researched along with Congenital Disorders of Glycosylation in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Brucker, W; Cassiman, D; Edmondson, AC; Garapati, K; Ghesquière, B; Johnsen, C; Kozicz, T; Krzysciak, W; Lam, C; Larson, A; Ligezka, AN; McGovern, RM; Mercimek-Andrews, S; Morava, E; Muthusamy, K; Oglesbee, D; Pandey, A; Perlstein, EO; Preston, G; Radenkovic, S; Ranatunga, W; Raymond, K; Reid, JM; Saraswat, M; Witters, P; Yanaihara, H | 1 |
| DiPrimio, N; Iyer, S; Lao, J; Morava, E; Murthy, K; Parton, Z; Perlstein, EO; Preston, G; Sam, FS; Tsang, H; Verheijen, J | 1 |
2 other study(ies) available for thiazolidines and Congenital Disorders of Glycosylation
| Article | Year |
|---|---|
Sorbitol Is a Severity Biomarker for PMM2-CDG with Therapeutic Implications.
Topics: Adolescent; Adult; Aged; Biomarkers; Child; Child, Preschool; Congenital Disorders of Glycosylation; Enzyme Inhibitors; Female; Glycosylation; Humans; Infant; Male; Middle Aged; Patient Acuity; Phosphotransferases (Phosphomutases); Prognosis; Rhodanine; Sorbitol; Thiazolidines; Young Adult | 2021 |
Repurposing the aldose reductase inhibitor and diabetic neuropathy drug epalrestat for the congenital disorder of glycosylation PMM2-CDG.
Topics: Aldehyde Reductase; Animals; Cells, Cultured; Congenital Disorders of Glycosylation; Diabetic Neuropathies; Disease Models, Animal; Drug Repositioning; Endoplasmic Reticulum Stress; Fibroblasts; Glycosylation; Humans; Nematoda; Phosphotransferases (Phosphomutases); Polyphenols; Rhodanine; Thiazolidines | 2019 |